Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: PG stock price vs MRK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MRK's multiple
Needs MRK P/E.
Implied fair value · at PG's multiple
Needs Annual EPS, PG P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
The Procter & Gamble Company · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Merck & Co., Inc. · implied price per share
Reporting currency could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
MRK · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
COLGATE PALMOLIVE CO
PG vs CL
KIMBERLY CLARK CORP
PG vs KMB
CHURCH & DWIGHT CO INC /DE/
PG vs CHD
CLOROX CO /DE/
PG vs CLX
Johnson & Johnson
PG vs JNJ
Pfizer Inc.
PG vs PFE
Eli Lilly and Company
PG vs LLY
Bristol-Myers Squibb Company
PG vs BMY
AbbVie Inc.
PG vs ABBV
AMGEN INC
PG vs AMGN
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe PG can sustain its premium earnings multiple despite slower growth and weaker margins than MRK, then hold or accumulate selectively; otherwise, the data support trimming exposure because PG is valued above MRK on P/E and EV/EBITDA while the implied price points to -19.4% downside.
On the provided P/E framework, PG trades at 22.2x versus MRK at 17.9x, yet the implied price is $116.43 versus PG's current price of $144.49, indicating a -19.4% downside. This suggests the market is paying a higher multiple for PG despite MRK showing stronger profitability and lower leverage on several metrics.
Supporting Metrics
